1-6 of 6
Dave M. Johnson
Close
Sort by
Journal Articles

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia

Clinical Trials & Observations
Jennifer R. Brown, John C. Byrd, Steven E. Coutre, Don M. Benson, Ian W. Flinn, Nina D. Wagner-Johnston, Stephen E. Spurgeon, Brad S. Kahl, Celeste Bello, Heather K. Webb, Dave M. Johnson, Sissy Peterman, Daniel Li, Thomas M. Jahn, Brian J. Lannutti, Roger G. Ulrich, Albert S. Yu, Langdon L. Miller, Richard R. Furman
Journal: Blood
Blood (2014) 123 (22): 3390–3397.
https://doi.org/10.1182/blood-2013-11-535047
Published: 2014
Includes: Supplemental data
Journal Articles

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)

Richard R. Furman, MD, Jeff P. Sharman, MD, Steven E. Coutre, MD, Bruce D. Cheson, MD, John M. Pagel, MD, PhD, Peter Hillmen, MBChB, PhD, Jacqueline C. Barrientos, MD, Andrew D. Zelenetz, MD, PhD, Thomas J. Kipps, MD, PhD, Ian Flinn, MD, PhD, Paolo Ghia, MD, PhD, Herbert Eradat, MD, Thomas Ervin, MD, Nicole Lamanna, MD, Michael Hallek, MD, Bertrand Coiffier, MD, PhD, Andrew R. Pettitt, PhD, FRCPath, Shuo Ma, MD, PhD, Stephan Stilgenbauer, MD, Paula Cramer, MD, Maria Aiello, Dave M. Johnson, Langdon L. Miller, MD, Daniel Li, PhD, Thomas M. Jahn, MD, PhD, Roger D. Dansey, MD, Susan M. O'Brien, MD
Journal: Blood
Blood (2013) 122 (21): LBA-6.
https://doi.org/10.1182/blood.V122.21.LBA-6.LBA-6
Published: 2013
Journal Articles

Combinations of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kdelta) Inhibitor GS–1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Results From a Phase I Study

Steven E. Coutre, MD, John P. Leonard, MD, Richard R. Furman, MD, Jacqueline C. Barrientos, MD, Sven de Vos, MD, PhD, Ian W. Flinn, MD, PhD, Marshall T. Schreeder, MD, Nina D. Wagner-Johnston, MD, Jeff Sharman, MD, Thomas E. Boyd, MD, Nathan H Fowler, MD, Leanne M. Holes, Brian J. Lannutti, PhD, Dave M. Johnson, Langdon L Miller, MD, Thomas M. Jahn, MD/PhD
Journal: Blood
Blood (2012) 120 (21): 191.
https://doi.org/10.1182/blood.V120.21.191.191
Published: 2012
Journal Articles

Comprehensive in Vitro and in Vivo Analysis of Phosphatidylinositol-3-Kinase Delta (PI3Kδ) Inhibition Using GS-1101 (CAL-101) in Combination with Mammalian Target of Rapamycin (mTOR) Inhibition Using Temsirolimus or Everolimus in Mantle Cell Lymphoma (MCL)

Paul M. Barr, MD, Francisco J. Hernandez-Ilizaliturri, MD, Thomas Murante, BS, Shannon P. Hilchey, PhD, Derick R Peterson, PhD, Jennifer L. Kelly, PhD, MPH, Dave M. Johnson, Brian J. Lannutti, PhD, Myron S. Czuczman, MD, Jonathan W. Friedberg, MD, Steven H. Bernstein, MD
Journal: Blood
Blood (2012) 120 (21): 3719.
https://doi.org/10.1182/blood.V120.21.3719.3719
Published: 2012
Journal Articles

Phosphoinositide 3'-Kinase (PI3K) Delta Inhibitor, GS-9820, Enhances Anti-Tumor Efficacy When Combined with Conventional Chemotherapeutic Agents in Primary Samples and Human Tumor Xenograft Model of Multiple Myeloma

Eric Sanchez, Mingjie Li, Cathy Wang, Haiming Chen, MD., Ph.D, Dave M. Johnson, Brian J. Lannutti, PhD, James R. Berenson, MD
Journal: Blood
Blood (2012) 120 (21): 4017.
https://doi.org/10.1182/blood.V120.21.4017.4017
Published: 2012
Journal Articles

A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, Cal-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Previously Treated, Indolent Non-Hodgkin Lymphoma (iNHL)

Sven de Vos, MD, PhD, Marshall T. Schreeder, Ian W. Flinn, MD, PhD, Steven E. Coutre, MD, John P. Leonard, MD, Nina D. Wagner-Johnston, Nathan H. Fowler, MD, Ralph V. Boccia, MD, Jaqueline C. Barrientos, MD, Thomas Boyd, MD, Jeff Sharman, MD, Leanne Holes, Brian Lannutti, Dave M. Johnson, Thomas M. Jahn, Langdon L Miller
Journal: Blood
Blood (2011) 118 (21): 2699.
https://doi.org/10.1182/blood.V118.21.2699.2699
Published: 2011